In order to accelerate the availability of innovative drugs, a pharmaceutical company is actively cooperating with Internet platforms

Recently, reports have shown that BeiGene's product Anjiawei (desulumab injection) has been officially launched in JD Pharmacy
.
It is reported that Angarve was developed by Amgen in the United States and has more than ten years of clinical application experience around the world.
Later, BeiGene and Amgen reached a global oncology strategic cooperation to obtain its authorization
.
The drug is the first RANKL inhibitor approved in China for the prevention of bone-related events involving bone metastases from solid tumors
.

.
It is worth noting that desulumab was approved by the National Medical Products Administration (NMPA) in May 2019 for the treatment of giant cell tumors of bone that may not be resected or surgically removed, which may cause severe dysfunction, including adults and skeletal development Mature
.
In addition, in April 2020, its New Indication Marketing Application (sNDA) for the prevention of bone-related events in patients with multiple myeloma and solid tumor bone metastases has also been formally accepted and is under technical approval by the Drug Evaluation Center
.
In this regard, the industry believes that the cooperation between the two parties is expected to bring more reliable guarantees for the treatment of giant cell tumors of bone, treatment of tumor bone metastasis and prevention of SREs for domestic cancer patients
.
Public information shows that giant cell tumor of bone is a primary borderline bone tumor with invasive and metastatic potential and characterized by osteolytic destruction
.
It has strong local invasiveness, high recurrence rate after tumor curettage, and long survival time of patients
.
In China, giant cell tumors of bone are very common, accounting for about 20% of all primary bone tumors
.
At present, with its good curative effect, Anjiawei has been included in the 2020 National Medical Insurance Drug List
.
The industry believes that Angavi’s launch of JD Pharmacy this time, for BeiGene, will join hands with JD Health to provide a nationwide undifferentiated drug supply and improve the one-stop specialty for patients with relevant indications in many aspects.
Improve the service experience and benefit more patients
.
In fact, JD Pharmacy has been deepening cooperation with global pharmaceutical and health brands to continuously improve the supply chain system covering all channels online and offline, and continuously improve professional service capabilities.

.
And continuously improve its medical and health one-stop and specialized service capabilities.
Through the professional service capabilities throughout the pre-diagnosis, during and after the diagnosis, we will provide one-stop management in patient disease education, patient disease management, and health management throughout the life cycle.
A series of innovative explorations
.
It is reported that in May 2021, JD Pharmacy has joined hands with many pharmaceutical companies to launch the "Single Disease Patient Care Center" including hepatitis, diabetes, and nutrition.
Through specialized professional operations, it is providing more patients with A more accurate and thoughtful one-stop service for medicine and health
.
In this context, the industry believes that in the future, as JD Pharmacy joins hands with more and more pharmaceutical companies, it will bring more patients a more versatile, convenient, professional, and high-quality medical and health service experience; Together, pharmaceutical companies continue to improve the availability of innovative drugs and bring continuous impetus to the accelerated implementation of inclusive healthcare
.